Skip to main content

Advertisement

Log in

An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting

Based on the results of the SOTI and TROPOS trials

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Introduction

Strontium ranelate is a new therapy for the treatment and prevention of osteoporosis that has been shown in two phase III clinical trials (the Spinal Osteoporosis Therapeutic Intervention [SOTI] and the Treatment Of Peripheral OSteoporosis Study [TROPOS] trials) to reduce the risk of osteoporotic fractures at the vertebral, non-vertebral and hip level in postmenopausal women. The aim of this study was to estimate the potential cost-effectiveness of strontium ranelate in the treatment of osteoporosis in postmenopausal Swedish patients.

Methods

A Markov cohort model was adapted to fit patients corresponding to the patients in the SOTI and TROPOS clinical trials. The model was populated with Swedish cost and epidemiological data. In the base case, the cost-effectiveness was estimated for 69-year old women with low bone mineral density (BMD) and prevalent vertebral fractures (SOTI) and for 77-year old women with low BMD (TROPOS). The cost-effectiveness analysis had a societal perspective.

Results

In the base case analysis, the cost per quality-adjusted life years (QALY) gained of strontium ranelate patients compared to no treatment patients was estimated at SEK 472,586 and SEK 259,643, including costs in added life years, based on the SOTI and the TROPOS trials, respectively. Excluding cost in added life years, the cost per QALY gained was estimated at SEK 336,420 (SOTI) and SEK 165,680 (TROPOS). In subgroup analyses, in patients 74 years and older with a T-score lower than −2.4 and patients older than 80 years of age, strontium ranelate was found to be cost saving compared to no treatment.

Conclusions

The results in the base case analyses and the sensitivity analyses of this study indicate that, compared to no treatment, strontium ranelate is cost-effective in the treatment of postmenopausal women with low BMD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350(5):459–468

    Article  PubMed  CAS  Google Scholar 

  2. Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90(5):2816–2822

    Article  PubMed  CAS  Google Scholar 

  3. Johnell O, Jonsson B, Jonsson L, Black D (2003) Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 21(5):305–314

    Article  PubMed  Google Scholar 

  4. Borgstrom F, Zethraeus N (2003) Economic assessment based on a clinical study of risedronate. Fracture prevention in elderly women with osteoporosis is cost-effective. Lakartidningen 100(1–2):36–40

    PubMed  Google Scholar 

  5. Borgstrom F, Johnell O, Jonsson B, Zethraeus N, Sen SS (2004) Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden. Bone 34(6):1064–1071

    Article  PubMed  Google Scholar 

  6. Jonsson L, Borgstrom F, Zethraeus N (2003) Cost-effectiveness of alendronate treatment of osteoporosis in Denmark. An economic evaluation based on the Fracture Intervention Trial. Ugeskr Laeger 165(43):4112–4116

    PubMed  Google Scholar 

  7. Kanis JA, Borgstrom F, Johnell O, Jonsson B (2004) Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporos Int 15(11):862–871

    Article  PubMed  CAS  Google Scholar 

  8. Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, Johnston CC Jr, Lindsay R (1998) Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 8(5):468–489

    Article  PubMed  CAS  Google Scholar 

  9. Seeman E, Vellas B, Meunier P, Roux C, Adami S, Aquino J, Semler J, Graham J, Sorensen O (2005) Vertebral and nonvertebral antifracture efficacy of strontium ranelate in very elderly women with osteoporosis. Osteoporos Int 16(Suppl 3):OC21:S6

    Google Scholar 

  10. European Medicines Agency. Summary of Product Characteristics (SPC). Available online at http://www.emea.eu.int/humandocs/PDFs/EPAR/protelos/H-560-PI-en.pdf

  11. Reginster JY, Meunier PJ (2003) Strontium ranelate phase 2 dose-ranging studies: PREVOS and STRATOS studies. Osteoporos Int 14(Suppl 3):S56–S65

    PubMed  CAS  Google Scholar 

  12. Reginster JY, Deroisy R, Dougados M, Jupsin I, Colette J, Roux C (2002) Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial. Osteoporos Int 13(12):925–931

    Article  PubMed  CAS  Google Scholar 

  13. Meunier PJ, Slosman DO, Delmas PD, Sebert JL, Brandi ML, Albanese C, Lorenc R, Pors-Nielsen S, De Vernejoul MC, Roces A, Reginster JY (2002) Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis—a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 87(5):2060–2066

    Article  PubMed  CAS  Google Scholar 

  14. Jonsson B (1998) Targeting high-risk populations. Osteoporos Int 8(Suppl 1):S13–S16

    PubMed  Google Scholar 

  15. Jonsson B, Christiansen C, Johnell O, Hedbrandt J, Karlsson G (1996) Cost-effectiveness of fracture prevention in established osteoporosis. Scand J Rheumatol Suppl 103:30–38

    PubMed  CAS  Google Scholar 

  16. Borgstrom F, Johnell O, Kanis JA, Oden A, Sykes D, Jonsson B (2004) Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics 22(17):1153–1165

    Article  PubMed  Google Scholar 

  17. Kanis JA, Borgstrom F, Johnell O, Oden A, Sykes D, Jonsson B (2005) Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporos Int 16(1):15–25

    Article  PubMed  CAS  Google Scholar 

  18. Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, de Laet C, Jonsson B (2000) Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int 11(8):669–674

    Article  PubMed  CAS  Google Scholar 

  19. Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12(5):417–427

    Article  PubMed  CAS  Google Scholar 

  20. Melton LJ 3rd, Crowson CS, O’Fallon WM (1999) Fracture incidence in Olmsted County, Minnesota: comparison of urban with rural rates and changes in urban rates over time. Osteoporos Int 9(1):29–37

    Article  PubMed  Google Scholar 

  21. Kanis JA, Johnell O, Oden A, Jonsson B, Dawson A, Dere W (2000) Risk of hip fracture derived from relative risks: an analysis applied to the population of Sweden. Osteoporos Int 11(2):120–127

    Article  PubMed  CAS  Google Scholar 

  22. de Laet CE, van Hout BA, Burger H, Hofman A, Pols HA (1997) Bone density and risk of hip fracture in men and women: cross sectional analysis. Br Med J 315(7102):221–225

    Google Scholar 

  23. Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Br Med J 312(7041):1254–1259

    CAS  Google Scholar 

  24. Kanis JA, Johnell O, de Laet C, Johansson H, Oden A, Delmas P, Eisman J, Fujiwara S, Garnero P, Kroger H, McCloskey EV, Mellstrom D, Melton LJ, Pols H, Reeve J, Silman A, Tenenhouse A (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35(2):375–382

    Article  PubMed  CAS  Google Scholar 

  25. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15(4):721–739

    Article  PubMed  CAS  Google Scholar 

  26. Statistics Sweden. Sweden’s Statistical Databases (SSD). Available online at http://www.scb.se/eng/databaser/ssd.asp

  27. Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D (2000) Risk of mortality following clinical fractures. Osteoporos Int 11(7):556–561

    Article  PubMed  CAS  Google Scholar 

  28. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353(9156):878–882

    Article  PubMed  CAS  Google Scholar 

  29. Cooper C, Atkinson EJ, Jacobsen SJ, O’Fallon WM, Melton LJ 3rd (1993) Population-based study of survival after osteoporotic fractures. Am J Epidemiol 137(9):1001–1005

    PubMed  CAS  Google Scholar 

  30. Jalava T, Sarna S, Pylkkanen L, Mawer B, Kanis JA, Selby P, Davies M, Adams J, Francis RM, Robinson J, McCloskey E (2003) Association between vertebral fracture and increased mortality in osteoporotic patients. J Bone Miner Res 18(7):1254–1260

    Article  PubMed  Google Scholar 

  31. Kanis JA, Oden A, Johnell O, de Laet C, Jonsson B (2004) Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 15(2):108–112

    Article  PubMed  Google Scholar 

  32. Oden A, Dawson A, Dere W, Johnell O, Jonsson B, Kanis JA (1998) Lifetime risk of hip fractures is underestimated. Osteoporos Int 8(6):599–603

    Article  PubMed  CAS  Google Scholar 

  33. Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, de Laet C, Jonsson B (2004) Mortality after osteoporotic fractures. Osteoporos Int 15(1):38–42

    Article  PubMed  CAS  Google Scholar 

  34. Poor G, Atkinson EJ, O’Fallon WM, Melton LJ 3rd (1995) Determinants of reduced survival following hip fractures in men. Clin Orthop Oct(319):260–265

    Google Scholar 

  35. Kanis J, Johnell O, Oden A, de Laet C, Jonsson B, Oglesby A (2002) Excess mortality after vertebral fracture. WHO Collaborating Centre for Metabolic Bone Diseases, Sheffield, UK

  36. Parker MJ, Anand JK (1991) What is the true mortality of hip fractures? Public Health 105(6):443–446

    Article  PubMed  CAS  Google Scholar 

  37. Kanis JA, Oden A, Johnell O, de Laet C, Jonsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. Bone 32(5):468–473

    Article  PubMed  CAS  Google Scholar 

  38. Läkemedelsförmånsnämndens allmänna råd (2003) Stockholm

  39. Zethraeus N, Stromberg L, Jonsson B, Svensson O, Ohlen G (1997) The cost of a hip fracture. Estimates for 1,709 patients in Sweden. Acta Orthop Scand 68(1):13–17

    Article  PubMed  CAS  Google Scholar 

  40. Zethraeus N, Borgström F, Johnell O, Kanis J, Jönsson B (2002) Costs and quality of life associated with osteoporosis related fractures—results from a Swedish survey. Working Paper Series in Economics and Finance, no 512, Stockholm School of Economics, Stockholm, Sweden

  41. Stockholms stads budgetavräkning 2003. Available online at http://www.stockholm.se/files/71600-71699/file_71645.pdf

  42. de Laet CE, van Hout BA, Burger H, Weel AE, Hofman A, Pols HA (1999) Incremental cost of medical care after hip fracture and first vertebral fracture: the Rotterdam study. Osteoporos Int 10(1):66–72

    Article  PubMed  Google Scholar 

  43. Meltzer D (1997) Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 16(1):33–64

    Article  PubMed  CAS  Google Scholar 

  44. Ekman M, Zethraeus N, Dahlstrom U, Hoglund C (2002) Cost-effectiveness of bisoprolol in chronic heart failure. Lakartidningen 99(7):646–650

    PubMed  Google Scholar 

  45. FASS för förskrivare. Home page at http://www.fass.se

  46. Priser för södra sjukvårdsregionen–Vårdtjänster per klinik (2003) Universitetssjukhuset i Lund

  47. Burstrom K, Johannesson M, Diderichsen F (2001) Swedish population health-related quality of life results using the EQ-5D. Qual Life Res 10(7):621–635

    Article  PubMed  CAS  Google Scholar 

  48. Kind P, Dolan P, Gudex C, Williams A (1998) Variations in population health status: results from a United Kingdom national questionnaire survey. Br Med J 316(7133):736–741

    CAS  Google Scholar 

  49. Kanis JA, Johnell O, Oden A, Borgstrom F, Zethraeus N, de Laet C, Jonsson B (2004) The risk and burden of vertebral fractures in Sweden. Osteoporos Int 15(1):20–26

    Article  PubMed  CAS  Google Scholar 

  50. Oleksik A, Lips P, Dawson A, Minshall ME, Shen W, Cooper C, Kanis J (2000) Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res 15(7):1384–1392

    Article  PubMed  CAS  Google Scholar 

  51. Brazier JE, Green C, Kanis JA (2002) A systematic review of health state utility values for osteoporosis-related conditions. Osteoporos Int 13(10):768–776

    Article  PubMed  CAS  Google Scholar 

  52. Tidermark J, Zethraeus N, Svensson O, Tornkvist H, Ponzer S (2002) Quality of life related to fracture displacement among elderly patients with femoral neck fractures treated with internal fixation. J Orthop Trauma 16(1):34–38

    Article  PubMed  Google Scholar 

  53. (2002) Översyn av samhällsekonomiska metoder och kalkylvården på transportområdet—ASEK review of cost benefit calculation. Methods and valuations in the transport sector. SIKA Rapport 4

  54. Persson U, Hjelmgren J (2003) Health services need knowledge of how the public values health. Lakartidningen 100(43):3436–3437

    PubMed  Google Scholar 

  55. Borgstrom F, Johnell O, Kanis JA, Oden A, Sykes D, Jönsson B (2004) Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden—an economic evaluation based on the MORE study. Pharmacoeconomics 22(17):1153–1165

    Article  PubMed  Google Scholar 

  56. (2003) PROTELOS—prevention and treatment of postmenopausal osteoporosis. Clinical Investigators’ brochure no 7

  57. Ross PD, Genant HK, Davis JW, Miller PD, Wasnich RD (1993) Predicting vertebral fracture incidence from prevalent fractures and bone density among non-black, osteoporotic women. Osteoporos Int 3(3):120–126

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgement

Financial support was obtained via an unrestricted grant from Servier.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to F. Borgström.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Borgström, F., Jönsson, B., Ström, O. et al. An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting. Osteoporos Int 17, 1781–1793 (2006). https://doi.org/10.1007/s00198-006-0193-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-006-0193-z

Keywords

Navigation